ライフサイエンスコーパス: subcutaneous injection

1 three doses 4 weeks apart), or placebo (all subcutaneous injection).

2 erience immobilisation and a mild procedure (subcutaneous injection).

3 female animals (1000 U/kg EPO or CEPO; three subcutaneous injections).

4 0-29-a 2-nt longer version of nusinersen-via subcutaneous injection.

5 nt for an extended period following a single subcutaneous injection.

6 intestinal lumen was absorbed, relative to a subcutaneous injection.

7 and properties was compared by 3T MRI after subcutaneous injection.

8 e by means of either aerosol inhalation or a subcutaneous injection.

9 y correlated with their concentrations after subcutaneous injection.

10 al level for prolonged period after a single subcutaneous injection.

11 -siRNA into mice through either tail vein or subcutaneous injection.

12 unotherapy via laser-generated micropores to subcutaneous injection.

13 drogel combination that lasted 4 weeks after subcutaneous injection.

14 the 2009 H1N1 influenza virus, compared with subcutaneous injection.

15 tal microneedles (MN) applied to skin or via subcutaneous injection.

16 in vivo sodium concentration detectors after subcutaneous injection.

17 cynomolgus monkeys and is bioavailable after subcutaneous injection.

18 cokinetic and safety profiles than IP6 after subcutaneous injection.

19 could be self-administered as a long-acting subcutaneous injection.

20 til week 50 as 40 mg per 0.4 mL citrate free subcutaneous injection.

21 lution, in a 3 mL prefilled Solostar pen for subcutaneous injection.

22 acterization of therapeutic antibodies after subcutaneous injection.

23 treatment option instead of a more expensive subcutaneous injection.

24 ab and placebo were administered by means of subcutaneous injection.

25 tment through both intravenous and non-local subcutaneous injections.

26 ks or 420 mg monthly) or matching placebo as subcutaneous injections.

27 g, n = 9) or placebo (n = 8), as six monthly subcutaneous injections.

28 y been re-investigated as an alternative for subcutaneous injections.

29 most previous studies, cocaine was given via subcutaneous injections.

30 weight gain, hypoglycaemia, and the need for subcutaneous injections.

31 , but are currently only approved for use as subcutaneous injections.

32 ombination of pertuzumab and trastuzumab for subcutaneous injection (1200 mg pertuzumab plus 600 mg t

33 significant difference (p>0.05) compared to subcutaneous injection (24+/-13min).

34 e glucocorticoid dexamethasone (10 mg/kg) by subcutaneous injection 30 minutes postinjury restores le

35 rats (n=18 male, n=18 female) received daily subcutaneous injections (40 microg/kg body weight) of BP

36 In conclusion, fondaparinux subcutaneous injection afforded significant advantages i

37 AAA animals (N = 15) underwent daily saline subcutaneous injection after PPE exposure.

38 ndaparinux because it does not require daily subcutaneous injection and is cheaper.

39 e of trafficking to the tumor site following subcutaneous injection and modulates transcription of se

40 e limitations of current DHE formulations in subcutaneous injection and nasal spray such as pain, adv

41 With the convenience of a subcutaneous injection and no requirement for renal moni

42 nificant limitations, including the need for subcutaneous injections and frequent monitoring.

43 rget sites relevant for epidural injections, subcutaneous injections and intraperitoneal access.

44 Subcutaneous injections and the sublingual route have be

45 tion route with the high efficacy known from subcutaneous injections and therefore represents a promi

46 ortezomib (1.3 mg/m(2); intravenous bolus or subcutaneous injection) and dexamethasone (20 mg oral or

47 imposed on CKD (5000 U/kg EPO or CEPO; three subcutaneous injections) and ischemia-reperfusion-induce

48 acept, 2.2 mg/kg (maximum, 160 mg) by weekly subcutaneous injection, and two 3-month courses of place

49 Notably, intravenous and subcutaneous injections are the only routes of administr

50 t hardly penetrated into the lungs following subcutaneous injection, as opposed to pulmonary delivery

51 The agonist was administered by subcutaneous injection at an initial dose of 0.05 mg per

52 study patients were randomized to receive 6 subcutaneous injections at 4-week intervals of either 30

53 , 16 or 32 mg/kg) at 1 h post-occlusion, and subcutaneous injections at 6 h and then once every 24 h

54 or vehicle at 1 h post-occlusion followed by subcutaneous injections at 6, 24 and 48 h.

55 erophore were both essentially avirulent via subcutaneous injection (bubonic plague model).

56 PR65 was administered by subcutaneous injection daily for 2 weeks to iron-deplete

57 Experience of repeated immobilisation and subcutaneous injection did not reverse the positive effe

58 phataemia received burosumab (0.8 mg/kg) via subcutaneous injection every 2 weeks for 64 weeks.

59 ive alirocumab (150 mg) or placebo as a 1-ml subcutaneous injection every 2 weeks for 78 weeks.

60 TEV-48125 given by subcutaneous injection every 28 days seems to be tolerab

61 ts) PF03512676 adjuvant were administered by subcutaneous injection every 3 weeks for a total of 4 in

62 r 300 mg in METREO) with placebo, given as a subcutaneous injection every 4 weeks for 52 weeks in pat

63 Patients received a 40 mg adalimumab subcutaneous injection every other week for 6 months.

64 Treatments were administered by two subcutaneous injections every 2 weeks for 10 weeks (tota

65 0 mg bimekizumab, which were administered as subcutaneous injections every 4 weeks for 12 weeks.

66 Study drugs were given as two subcutaneous injections every 4 weeks for the first thre

67 ter study of nemolizumab (10, 30, and 90 mg) subcutaneous injections every 4 weeks versus placebo, wi

68 than intracerebroventricular administration; subcutaneous injections extended the median lifespan by

69 6h in chemical-induced diabetes mice, while subcutaneous injection failed to maintain blood glucose

70 tarted on denosumab 60 mg every 6 months via subcutaneous injection for 12 months.

71 (420 mg) (n = 484) or placebo (n = 484) via subcutaneous injection for 76 weeks, in addition to stat

72 Subjects received 100 mg anakinra by subcutaneous injection for 84 days, followed by a 180-da

73 tiramer acetate (20 mg), or placebo by daily subcutaneous injection for 9 months.

74 andard dose) or 40 mug (high dose) daily via subcutaneous injection for 9 months.

75 eive 25 mg clazakizumab or placebo (4-weekly subcutaneous injections) for 12 weeks (part A), followed

76 e either sildenafil 10 mg/kg/d or placebo by subcutaneous injection from GD24 to GD30.

77 mulated strong IFN-alpha responses following subcutaneous injection, had robust antiviral activity th

78 To desensitize allergic individuals, subcutaneous injection immunotherapy or sublingual immun

79 Following subcutaneous injection in a diabetic rat, the analog eff

80 -retinoids was achieved in Lrat(-/-) mice by subcutaneous injection in a microparticle/hydrogel drug-

81 ation of (99m)Tc-SPIONs in lymph nodes after subcutaneous injection in animals, verified by SPECT/MRI

82 gents reach therapeutic concentrations after subcutaneous injection in nonhuman primates.

83 g-dose trial of inclisiran administered as a subcutaneous injection in patients at high risk for card

84 by intra-oral injection was as effective as subcutaneous injection in promoting tooth extraction soc

85 -week treatment period administered by daily subcutaneous injections in their homes by trained caregi

86 3.6 mg/mL in a 3 mL prefilled PDS290 pen for subcutaneous injection; in the IGlar U100 group, patient

87 NO2-Tyr(166)-apoA-I, after subcutaneous injection into hLCAT(Tg/Tg), apoA-I(-/-) mi

88 m patient-derived xenografts was assessed by subcutaneous injection into nonobese diabeteic.Cg-Prkdc(

89 pens to therapeutic antibodies in vivo after subcutaneous injection is of high interest.

90 ho(-/-) mice at postnatal day 10 as a single subcutaneous injection mixed with a basement membrane ma

91 crylate) were first characterized in a mouse subcutaneous injection model.

92 , respectively, 35%, 29% and 23% that of the subcutaneous injection of 1 U kg(-1) insulin.

93 After a single subcutaneous injection of 100 microg/kg, approximately 1

94 The first cohort received one subcutaneous injection of 2 mg/kg RG-101 or placebo; the

95 water, in response to hypovolemia induced by subcutaneous injection of 30% polyethylene glycol soluti

96 1 or placebo; the second cohort received one subcutaneous injection of 4 mg/kg or placebo.

97 Furthermore, subcutaneous injection of 5 ug of the probe in intact or

98 0.5-mL subcutaneous injection of 500 ug of adjuvanted (1 dose)

99 Patients received 1 subcutaneous injection of 60 mg gevokizumab at baseline

100 enerated randomisation schedule to receive a subcutaneous injection of 7.5 mg, 22.5 mg, 75 mg, or 225

101 eceiving an anti-myostatin PINTA745 (n = 12; subcutaneous injection of 7.5 mg.kg(-1) PINTA745 immedia

102 In WT mice in vivo, subcutaneous injection of 8-OH-DPAT produced similar bip

103 puter-generated random sequence to receive a subcutaneous injection of 80 mg ixekizumab every 4 weeks

104 models: xenografts produced in F344 rats by subcutaneous injection of 9L tumor cells and transgenic

105 interstitial fluid and serum samples after a subcutaneous injection of a therapeutic antibody into a

106 dle cell/pleomorphic sarcomas after a single subcutaneous injection of adenovirus carrying Cre-recomb

107 Morphologically, subcutaneous injection of all PPCLs into mice yielded tu

108 ients, respectively, were treated with daily subcutaneous injection of AM0010.

109 assessed by comparison with intradermal and subcutaneous injection of antigen using a 27G needle and

110 opathy, NaV1.8 shRNA vector was delivered by subcutaneous injection of cationized gelatin/plasmid DNA

111 Inflammation was induced in C57BL/6 mice by subcutaneous injection of complete Freund adjuvant in th

112 ) mice were treated with a single 200-microg subcutaneous injection of CRP or control reagents either

113 motherapy: subcutaneous low-dose cytarabine (subcutaneous injection of cytarabine 20 mg twice daily o

114 xpression of IL-33 in quiescent vessels, and subcutaneous injection of DAPT in healthy skin reduced I

115 and litters exposed to MS15 with concurrent subcutaneous injection of devazepide or vehicle.

116 eptive stimulation was carried out through a subcutaneous injection of dilute formalin (50muL, 10%) i

117 ere randomly assigned (1:1) to either weekly subcutaneous injection of dulaglutide (1.5 mg) or placeb

118 ere randomly assigned (1:1) to either weekly subcutaneous injection of dulaglutide (1.5 mg) or placeb

119 computer-generated blocked randomisation to subcutaneous injection of either 2 mg/kg (maximum 300 mg

120 Animals received a subcutaneous injection of either 250,000 cells of the tr

121 We randomly assigned patients to receive a subcutaneous injection of either erenumab, at a dose of

122 d participants (1:1) by country to receive a subcutaneous injection of either mepolizumab 100 mg or p

123 were randomly assigned to receive one daily subcutaneous injection of enoxaparin 40 mg or placebo un

124 In a syngeneic model of tumor progression, subcutaneous injection of EO771 cells formed faster-grow

125 tudied on two occasions, with a double-blind subcutaneous injection of EX (5 mug) or placebo (PLC) 30

126 BALB/c mice received subcutaneous injection of FITC-conjugated dextran (DX) p

127 Healthy volunteers received a single subcutaneous injection of fitusiran (at a dose of 0.03 m

128 r results indicated that subconjunctival and subcutaneous injection of HC-HA/PTX3 preserved tear secr

129 The hypothesis was tested by means of subcutaneous injection of human muscle precursor cells f

130 mg per deciliter in a 3:1 ratio to receive a subcutaneous injection of inclisiran or placebo in eithe

131 veitis (EAU) was induced in B10.RIII mice by subcutaneous injection of interphotoreceptor retinoid-bi

132 ly assigned participants to receive a single subcutaneous injection of ISIS-APO(a)Rx (50 mg, 100 mg,

133 A recent study demonstrated that a single subcutaneous injection of isoproterenol (ISO; 200 mg/kg)

134 Subcutaneous injection of jacalin into neonatal mice dra

135 ulation, 53 women were administered a single subcutaneous injection of kisspeptin-54 (1.6 nmol/kg, n

136 In addition, subcutaneous injection of KLK-5 in SOD3 knockout mice ex

137 EIU was induced by subcutaneous injection of lipopolysaccharide (LPS) (200

138 EIU in Lewis rats was induced by subcutaneous injection of lipopolysaccharide (LPS) follo

139 EIU in Lewis rats was developed by subcutaneous injection of lipopolysaccharide (LPS; 150 m

140 EIU in Lewis rats was developed by the subcutaneous injection of lipopolysaccharide (LPS; 150 m

141 EIU was induced by subcutaneous injection of lipopolysaccharide (LPS; 150 m

142 Treatment for 16 weeks with once-daily subcutaneous injection of liraglutide or placebo.

143 synaptosomes, and in striatum of rats given subcutaneous injection of METH.

144 Subcutaneous injection of mice with PF-04178903 was init

145 cell RNA sequencing, in vitro coculture, and subcutaneous injection of MSCs and myeloma cells into mi

146 duced in these animals (and controls) by the subcutaneous injection of myelin oligodendrocyte glycopr

147 Mice in pretreatment were treated with a subcutaneous injection of N-acetylcysteine before the fo

148 ) were randomly assigned to receive a single subcutaneous injection of one of five ascending doses of

149 Subcutaneous injection of PEG-PH20 delays the onset of E

150 tage SCLC grew in immunodeficient mice after subcutaneous injection of PNEC-containing cultures in wh

151 Furthermore, subcutaneous injection of recombinant TWEAK into naive m

152 e performed on tumor-bearing nude mice after subcutaneous injection of RIN-m5F cells.

153 Subcutaneous injection of SIB-1508Y (10 mg/kg) increased

154 In this model, subcutaneous injection of SK5 cells with short hairpin R

155 Subcutaneous injection of Tat-Smad7 attenuated infiltrat

156 Participants received a subcutaneous injection of TDV or placebo on days 0 and 9

157 multiple peptidic cargoes can be achieved by subcutaneous injection of the construct.

158 segment (ROS) interface were observed after subcutaneous injection of the drug-loaded delivery combi

159 ections with saline (control); (ii) a single subcutaneous injection of the gonadotropin-releasing hor

160 tion of the jugular vein was performed after subcutaneous injection of the peptide in rats (n=4 per p

161 Subcutaneous injection of the PGE(2) analog misoprostol

162 A single subcutaneous injection of the same variant in rabbits re

163 After a single subcutaneous injection of the vascular endothelial growt

164 Participants were given a subcutaneous injection of their allocated treatment at d

165 In wild-type mice, the subcutaneous injection of trehalose dimycolate-coated po

166 Subcutaneous injection of TRIM24 iHMECs in nude mice led

167 After subcutaneous injection of tumor cell lines of different

168 We generated a murine GBM xenograft via subcutaneous injection of U87-MG GBM cells and found tha

169 This was immediately followed by subcutaneous injection of vehicle, mifepristone 30 mg/kg

170 Arterial calcification was induced by subcutaneous injection of vitamin D(3) or by adventitial

171 Subcutaneous injection of XPC-deficient keratinocytes in

172 range, 30-85 years) who received intradermal subcutaneous injections of 0.31-100 microg indocyanine g

173 One hundred patients received subcutaneous injections of 1 mg twice per day of CrA and

174 ted (1:1) by an external service provider to subcutaneous injections of 10(8) plaque-forming units of

175 derate-to-severe plaque psoriasis to receive subcutaneous injections of 10, 25, 75, or 150 mg of ixek

176 parate experiment, Ldlr(-/-) mice were given subcutaneous injections of 27HC and placed on regular ch

177 NMDA receptors (NMDARs) during development [subcutaneous injections of 30 mg/kg ketamine (KET) on po

178 , 38, and 46 (plus injections of placebo) or subcutaneous injections of 40 mg of adalimumab, with a t

179 Subcutaneous injections of 500 mug of lipid-free apoA-I

180 Repeated subcutaneous injections of a monoclonal antibody against

181 , or their littermates (controls) were given subcutaneous injections of a syngeneic KPC-derived PDAC

182 ent peripheral corneal infiltrates following subcutaneous injections of adalimumab.

183 Activation of Tie2 by subcutaneous injections of AKB-9778 combined with suppre

184 scid)Il2rg(tm1Wjl)/SzJ (NSG) mice were given subcutaneous injections of AMC-EAC-007B cells and also g

185 Mice were treated with single subcutaneous injections of AMD3100 (5 mg/kg) or saline a

186 40 mg, or matching placebo every 2 weeks; or subcutaneous injections of AMG 145 280 mg, 350 mg, or 42

187 ough an interactive voice response system to subcutaneous injections of AMG 145 70 mg, 105 mg, or 140

188 ugh an interactive voice response system, to subcutaneous injections of AMG 145 70 mg, 105 mg, or 140

189 Its pharmacological inhibition by subcutaneous injections of an anti-myostatin peptibody i

190 After repeated subcutaneous injections of anti-mLAMalpha3 IgG erosions

191 We also determined the effect of subcutaneous injections of AZD8529 (20 and 40 mg/kg) on

192 for cancer treatment received two successive subcutaneous injections of azoxymethane (AOM) at 20mg/kg

193 Rats received subcutaneous injections of CORT for 3 weeks and Reelin w

194 er avoidance stress each day, or given daily subcutaneous injections of corticosterone, for 10 consec

195 Subcutaneous injections of CsA-loaded DIANAs in mice pro

196 Weekly subcutaneous injections of drug nanoformulations at dose

197 omly assigned to groups that received weekly subcutaneous injections of dupilumab (300 mg, n = 23) or

198 with moderate-to-severe psoriasis to receive subcutaneous injections of either 45 or 90 mg of ustekin

199 l, we administered a series of three monthly subcutaneous injections of either benralizumab (at a dos

200 randomized to groups that were given up to 6 subcutaneous injections of either etanercept or placebo

201 BN rats received subcutaneous injections of either saline or one of two d

202 C57BL/6 mice were untreated (UT) or received subcutaneous injections of either scopolamine hydrobromi

203 Four days later, animals received daily subcutaneous injections of either the synthetic GLP-1 re

204 were randomized to 3 months monotherapy with subcutaneous injections of elamipretide (0.5 mg/kg once

205 Daily subcutaneous injections of enoxacin, bis-enoxacin, alend

206 lly, subsequent studies tested the mice with subcutaneous injections of etidronate.

207 y assigned in a 2:1 ratio to receive monthly subcutaneous injections of evolocumab (420 mg) or placeb

208 ease were randomly assigned (1:1) to receive subcutaneous injections of exenatide 2 mg or placebo onc

209 previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at

210 eeks were equivalent to or better than daily subcutaneous injections of free Ex-4 solution (20 mug/kg

211 They received seven subcutaneous injections of GD2/GD3 vaccine spanning 1 ye

212 were randomized (1:1) to received 4 weeks of subcutaneous injections of GM-CSF (leukine), 500 mug/day

213 Subcutaneous injections of golimumab or placebo were adm

214 It involves subcutaneous injections of granulocyte-colony-stimulatin

215 use and C-reactive protein concentration) to subcutaneous injections of guselkumab 100 mg every 4 wee

216 On days 2, 4, and 6, subjects received subcutaneous injections of IFN-gamma (100 mug/day; n = 6

217 ous familial hypercholesterolemia to receive subcutaneous injections of inclisiran sodium (at a dose

218 ong metabolic disease that requires frequent subcutaneous injections of insulin.

219 gle-dose part of the study or to receive six subcutaneous injections of ISIS-APO(a)Rx (100 mg, 200 mg

220 y weight, while receiving either twice daily subcutaneous injections of leptin or placebo.

221 nducted in four UK medical centres to assess subcutaneous injections of liraglutide (1.8 mg daily) co

222 atients in a 2:1 ratio to receive once-daily subcutaneous injections of liraglutide at a dose of 3.0

223 -2Rgamma(-/-) (NSG) mice were given cecal or subcutaneous injections of LS-174T or human primary CRC

224 ce wheel-running behavior in response to 3 d subcutaneous injections of melatonin in the late day.

225 ere randomly assigned to receive five weekly subcutaneous injections of miravirsen at doses of 3 mg,

226 ntly 5 or 12 weeks later boosted by 3 weekly subcutaneous injections of MVATG16643.

227 EAE mice were given subcutaneous injections of myelin oligodendrocyte glycop

228 reactivity was immunized by a skin graft and subcutaneous injections of peripheral blood monocyte cel

229 psoriasis were randomly assigned to receive subcutaneous injections of placebo (n = 113), golimumab

230 1:1:1) by a computer-based system to receive subcutaneous injections of placebo once a day, 10 mg peg

231 ed to a double-blind trial of 12 once-weekly subcutaneous injections of placebo or 0.8 mg of etanerce

232 omputer-generated random sequence to receive subcutaneous injections of placebo or 315 mg LY at weeks

233 ose group) were randomly assigned to receive subcutaneous injections of placebo or an antisense oligo

234 studies to an in vivo setting, we performed subcutaneous injections of PPARgamma-expressing fibrobla

235 rats, ovariectomized for 1 week, were given subcutaneous injections of PPT (10 mg kg(-)(1)), oestrad

236 en-label, phase 1, multicentre trial, single subcutaneous injections of rAvPAL-PEG were given in esca

237 assigned a total of 166 patients to receive subcutaneous injections of risankizumab (a single 18-mg

238 the standard of care (77 patients) or weekly subcutaneous injections of romiplostim (157 patients).

239 Children received subcutaneous injections of romiplostim (n = 17) or place

240 0(9)/L or less were randomly assigned 2:1 to subcutaneous injections of romiplostim (n=42 in splenect

241 Animals received subcutaneous injections of saline or liraglutide (0.005-

242 were randomly assigned to group 1 (control): subcutaneous injections of saline solution, three times

243 PSC were randomized 1:1:1 to receive weekly subcutaneous injections of simtuzumab 75 mg, simtuzumab

244 ecific small hairpin RNAs or that were given subcutaneous injections of siRNAs had reduced levels of

245 l hypertension in mice; some mice were given subcutaneous injections of sivelestat or underwent bile-

246 iven intraperitoneal injections of S100A8 or subcutaneous injections of Staphylococcus aureus.

247 Participants self-administered daily subcutaneous injections of tesamorelin (Theratechnologie

248 Multiple subcutaneous injections of the insulin containing formul

249 ngioedema were initially administered weekly subcutaneous injections of the unconjugated parent drug,

250 Subcutaneous injections of these complexes showed enhanc

251 underwent a second randomization to receive subcutaneous injections of ustekinumab (90 mg) or placeb

252 r wild-type donors, and treated with 7 daily subcutaneous injections of VIPhyb (peptidic VIP-antagoni

253 lisiran (284 mg) or placebo, administered by subcutaneous injection on day 1, day 90, and every 6 mon

254 g/m(2)) was given as an intravenous bolus or subcutaneous injection on days 1, 4, 8, and 11 of 21-day

255 when administered at 10 or 100 microg/kg by subcutaneous injection once daily.

256 Y2951742 (150 mg) or placebo were given as a subcutaneous injection once every 2 weeks for 12 weeks.

257 Participants were randomly assigned (1:1) subcutaneous injections once a week of either dulaglutid

258 Treatment consisted of subcutaneous injections once per week from week 1 to 4,

259 e chemiluminescence in vivo images following subcutaneous injection, only the NIR probe could provide

260 Immunization of mice by subcutaneous injection or epicutaneous laser microporati

261 of 0.1 microg/kg when administered by either subcutaneous injection or oral delivery.

262 increased their ability to form tumors after subcutaneous injection or orthotopic transplantation int

263 abel trial evaluated the effects of 4 weekly subcutaneous injections or 1 intravenous infusion of ust

264 peginterferon alfa 2a (180 mug once weekly, subcutaneous injection) or 2b (according to bodyweight;

265 tant therapy) to once-weekly exenatide (2 mg subcutaneous injection) or once-daily glargine (titrated

266 file and a systemic uptake >10% of that of a subcutaneous injection over a 4-h sampling period.

267 Treatments were administered by subcutaneous injection; patients assigned to 50 mg siruk

268 em, to receive once-weekly exenatide 2 mg by subcutaneous injection plus once-daily dapagliflozin 10

269 g, 100 mug, 120 mug, or 150 mug once weekly, subcutaneous injection), plus ribavirin (1000-1200 mg/da

270 ombination of pertuzumab and trastuzumab for subcutaneous injection provides non-inferior cycle 7 per

271 administration of 20-40 mug/kg/d of IL-15 by subcutaneous injection resulted in a more modest (10-fol

272 1 inhibitor preparation that is suitable for subcutaneous injection, resulted in functional levels of

273 bution and PET studies after intravenous and subcutaneous injections showed similar patterns and kine

274 Simvastatin treatment (20mg/kg, bolus subcutaneous injection) significantly improved clinical

275 local skin inflammatory reaction limited to subcutaneous injection site and elicited no other toxic

276 of a novel in vitro system, termed Scissor (Subcutaneous Injection Site Simulator).

277 clearance and slow release kinetics from the subcutaneous injection site.

278 domly assigned 323 patients to receive three subcutaneous injections, spaced 4 weeks apart, of omaliz

279 e (n = 154) or placebo (n = 146) via a daily subcutaneous injection; study drug was advanced to a dos

280 omiplostim is a TPO peptide mimetic given by subcutaneous injection that activates the TPO receptor b

281 y 2 weeks off) or IFN-alpha (9 million units subcutaneous injections, three times weekly).

282 f 400 U per kilogram three times per week by subcutaneous injection through 32 completed weeks of pos

283 On subcutaneous injection to neonatal mice, the TLR8 agonis

284 to self-administer a single 30-mg icatibant subcutaneous injection to treat their next attack.

285 d aluminum hydroxide) were administered as 5 subcutaneous injections to 239 adults with allergic rhin

286 a single intracerebroventricular or multiple subcutaneous injections to leptin receptor-deficient (db

287 ined to open-label nadroparin (3800 IU daily subcutaneous injections) treatment (n = 67) in the setti

288 dosages of 0.045-0.05 mg/kg per day by daily subcutaneous injections until the patient has reached th

289 ation) within the fixed-dose combination for subcutaneous injection versus intravenous pertuzumab plu

290 tial loading dose of 300 mg of rilonacept by subcutaneous injection, were evaluated 6 and 10 days lat

291 We have found that daily subcutaneous injection with a maximum tolerated dose (MT

292 ct via laser-generated skin micropores or by subcutaneous injection with or without alum.

293 Lastly, we showed in mice that subcutaneous injection with recombinant IL-17A, IL-22, o

294 nergy expenditure in mice was measured after subcutaneous injection with vehicle, 1 mg norepinephrine

295 thin 14 days of hospital discharge, to daily subcutaneous injections with anakinra 100 mg for 2 weeks

296 ed by geographical region, to receive weekly subcutaneous injections with atacicept (25, 75, or 150 m

297 nificantly different (p>0.05) as compared to subcutaneous injection, with a relative bioavailability

298 : oral gavage, intraperitoneal injection, or subcutaneous injection, with doses varying between 2 and

299 All patients received weekly subcutaneous injections, with the active treatment group

300 intake in lean pigs for up to 48 h after one subcutaneous injection without adverse effects, a plasma